BDX logo

Becton Dickinson

BDX · What the business does, what can go wrong, and how options sellers approach it

What it does

Becton, Dickinson and Company (BD) is a global medical technology company. It makes the everyday tools of healthcare: needles, syringes, catheters, and sharps-disposal containers. It also makes drug-delivery devices, infusion and medication-management systems, and products used in surgical and interventional care.

Its portfolio has been reshaped over time, so the segment mix can change. Its core identity is supplying hospitals, clinics, labs, and drugmakers with high-volume medical products.

How it makes money

BD sells devices and consumables, many of them used again and again, to hospitals, health systems, distributors, and pharmaceutical companies. Some systems, like infusion pumps, are placed in hospitals and paired with disposable supplies and service.

Drugmakers also use BD's injection and prefilled-device technology to deliver their medicines, and sales outside the United States are a meaningful part of the business.

Why investors own it

  • Recurring demand: Many products are used in routine care, so volumes tend to be steady across economic cycles.
  • Scale: A large installed base and long hospital relationships can make BD hard to displace.
  • Dividend: The company has a long record of paying dividends, which appeals to income-minded holders.

What can go wrong

  • Regulation and quality: Medical devices are tightly regulated. Recalls, warning letters, or product problems can be costly and damage trust.
  • Pricing pressure: Hospitals and purchasing groups negotiate hard on price.
  • Portfolio changes: Spinoffs, acquisitions, and integration can distract management and disappoint.
  • Supply and costs: Manufacturing disruptions, raw material costs, and currency swings can hurt margins.
  • Litigation: Product liability claims are a recurring risk in medical devices.

What to watch

  • Organic revenue growth by segment
  • Hospital procedure volumes
  • Operating margin trends
  • Free cash flow and debt levels
  • FDA actions, recalls, or product approvals
  • Pharma demand for prefilled devices

Options income angle

Options on BDX trade across many strikes and expirations, with liquidity best in near-dated, near-the-money contracts and thinner than in the most heavily traded stocks.

Implied volatility tends to rise ahead of earnings, guidance updates, and regulatory or portfolio news, then often fades.

A caution for premium sellers: a stable, defensive stock can still gap sharply on earnings or a regulatory surprise. A covered call caps upside, and a cash-secured put can leave you owning shares after a sharp drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended September 30, 2025, filed November 25, 2025. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

BD reported fiscal 2025 revenue of $21.840 billion, up 8.2%, with the Advanced Patient Monitoring acquisition supplying much of the growth. Diluted earnings per share from continuing operations were $5.82, against $5.86 the year before. The filing also centers on the planned combination of the Biosciences and Diagnostic Solutions business with Waters, expected to close around the end of the first quarter of calendar year 2026.

How the business did

  • Of the 8.2% revenue increase, the Advanced Patient Monitoring acquisition added 4.8% and volume/other added 3.2%. Pricing subtracted 0.3%.
  • Medical revenue was $11,456 million, up 13.7%. Interventional was $5,217 million, up 4.8%. Life Sciences was $5,167 million, down 0.5%, with Biosciences down 3.6% as instrument sales were hurt by market conditions.
  • Net income from continuing operations was $1,678 million, against $1,705 million the year before. Gross profit margin was 45.4%, against 45.2%. "Specified items," which management separates out as unusual or acquisition-related, totaled $2,951 million. These included $1,898 million of purchase accounting adjustments and a $336 million inventory step-up tied to the acquisition.
  • Cash flow from continuing operations was $3.430 billion. The company paid $1.196 billion in dividends, repurchased approximately $1 billion of stock and paid $175 million for the SEC investigation. Total debt was $19,181 million.

Risks specific to this company

  • Waters deal: The combination needs regulatory approvals, Waters stockholder approval and an IRS private letter ruling. If it fails or is delayed, BD bears significant non-recurring costs. If it is found taxable, BD and its shareholders could face significant tax liabilities.
  • Infusion pump oversight: The CareFusion 303 subsidiary operates under an amended FDA Consent Decree covering BD Alaris pumps. Two FDA warning letters also cover the Dispensing and Specimen Management businesses. Replacing or remediating Alaris devices is expected to be substantially complete over the next calendar year.
  • Tariffs: BD expects tariffs to adversely affect operating expense in fiscal year 2026 and possibly beyond. A Section 232 investigation into medical imports adds further uncertainty.
  • Litigation: Pending claims involve ethylene oxide, hernia repair implants, women's surgical continence and pelvic organ prolapse products, vena cava filters and implantable ports. For some product claims, BD has limited or no remaining insurance.
  • Sterilization rules: Ethylene oxide regulation could force BD or its third-party sterilizers to suspend operations or add costs. BD is working toward compliance with the EPA emissions standard by April 2028.
  • Demand pressure: China's volume-based procurement programs, reduced government research funding and lower vaccine demand have hurt results.

What management is watching

  • Tariff effects in fiscal 2026, and whether sourcing changes and exemptions work as mitigation.
  • The Waters closing, and a reorganization into five segments effective October 1, 2025: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences.
  • Investment in the pipeline: research and development expense of $1,265 million, capital spending of $760 million (mostly manufacturing capacity), and tuck-in acquisitions.
  • Measures management reviews: gross profit margin, selling and administrative expense, return on invested capital, cash flows and results on a foreign currency-neutral basis, which strips out exchange-rate effects.
  • Capital return and borrowing: $250 million of stock was repurchased in November 2025. The revolving credit facility carries a leverage coverage ratio limit of 4.25-to-1, and $855 million of commercial paper was outstanding at year end.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended June 30, 2026, filed August 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Becton Dickinson reported third-quarter revenue of $4.983 billion, up 5.4% from the prior-year period, but profit was flat. Net income from continuing operations was $451 million in both periods, because tariffs, labor costs and costs tied to an FDA warning letter at the El Paso plant squeezed margins. This was the first full quarter after the February 9, 2026 spin-off of the Biosciences and Diagnostic Solutions business to Waters.

How the business did

  • Revenue: The 5.4% increase came from volume/other of 4.1%, pricing of 0.3% and foreign currency of 1.0%. On a foreign currency-neutral basis (which strips out exchange-rate effects), growth was 4.4%. Advanced Patient Monitoring rose 10.9%, and BioPharma Systems rose 6.6%, led by GLP-1 delivery products. China's volume-based procurement programs (VoBP), government purchasing programs meant to contain healthcare costs, weighed on several units.
  • Profit: Diluted earnings per share from continuing operations were $1.64, versus $1.57 a year earlier. For the nine months they were $2.58, versus $2.62. Gross margin fell to 46.4% from 47.3%. Management cited tariffs, higher labor costs and El Paso Warning Letter costs, partly offset by lower manufacturing costs. Segment income margins narrowed in Medical Essentials (36.8%), Connected Care (32.3%) and Interventional (39.9%), and rose in BioPharma Systems (38.6%).
  • Unusual items: Nine-month restructuring costs included non-cash asset impairment charges of $450 million, recorded when the company committed to exit activities that no longer fit its strategy. Total specified items, which are one-off or accounting-driven charges management separates out, were $538 million for the quarter.
  • Cash and capital return: Cash flow from continuing operating activities was $2.104 billion for the first nine months, versus $1,578 million a year earlier. The company paid $875 million in dividends and about $2.250 billion for share repurchases. Total debt was $16,808 million, down from $19,180 million at September 30, 2025.

What management is watching

  • Tariffs and supply chain: Management expects tariffs to keep adding to operating expense for fiscal 2026 and possibly beyond. It also says continued disruption tied to the conflict in Iran and the Middle East could raise supply chain costs, though it has not yet significantly affected distribution.
  • FDA matters: The El Paso Warning Letter, issued April 30, 2026, cites manufacturing quality deficiencies. The company has committed to independent quality assessments and certain product recalls, and says the liability it has recorded could prove too low. The remediation or replacement of BD Alaris infusion systems in the U.S. is expected to be substantially complete this calendar year.
  • Investment and measures: The company says it continues to invest in research and development, tuck-in acquisitions and geographic expansion under its "Excellence Unleashed" strategy. It points investors to foreign currency-neutral results as one measure of performance.

Follow BDX in Kortex

The Kortex app shows BDX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.